NFKB1 and central nervous system cancer: The results showed that NF-κB inhibitor BAY11–7082 significantly decreased the mRNA and protein expression levels of IL-6 in BV2 cells activated by CM from GL261 or ALTS1C1 glioma cells (Figures 2B, C, Supplementary Figure S4A-B).